Physician profile
Jan E Phillips
NPI 1760653315
$4,185.87
in general payments reported to CMS, 2019-2025
22 companies · $446 in 2025
The $446 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $538 · 2020: $300 · 2021: $515 · 2022: $801 · 2023: $857 · 2024: $729 · 2025: $446.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,032.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,031.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,125.41 | 2019-2023 | Xarelto |
| Pfizer INC. | $708.32 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $523.96 | 2019-2025 | Dificid, Verquvo, Zerbaxa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $312.95 | 2019-2025 | Jardiance |
| Alexion Pharmaceuticals, INC. | $290.27 | 2021-2025 | Ultomiris, Soliris |
| Abbvie INC. | $227.04 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $211.13 | 2019-2023 | Xifaxan |
| Novartis Pharmaceuticals Corporation | $133.32 | 2019-2024 | |
| Gilead Sciences, INC. | $106.20 | 2023-2024 | Veklury |
| E.R. Squibb & Sons, L.L.C. | $93.14 | 2019-2025 | Eliquis |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $88.30 | 2019 | |
| Vertex Pharmaceuticals Incorporated | $73.01 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $63.70 | 2025 | Vowst |
| Shionogi INC | $58.62 | 2023-2024 | Fetroja |
| Fisher & Paykel Healthcare INC | $47.63 | 2023 | Fisher & Paykel Healthcare |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $24.44 | 2021 | |
| Shire North American Group INC | $23.20 | 2019 | |
| Vifor Pharma, INC. | $16.57 | 2021 | |
| Amgen INC. | $15.57 | 2019 | |
| Bridgebio Pharma, INC. | $15.10 | 2025 | Attruby |
| Scpharmaceuticals INC. | $14.23 | 2023 | |
| Allergan, INC. | $13.76 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jan Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.